Amyotrophic Lateral Sclerosis and the Innate Immune System
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02869048|
Recruitment Status : Recruiting
First Posted : August 16, 2016
Last Update Posted : October 6, 2017
Amyotrophic Lateral Sclerosis (ALS) is an aggressive, deadly disease. ALS leads to destruction of the neural pathways which control the conscious movements of the muscles. This destruction leads to muscular dystrophy with increasing difficulties in moving, breathing, swallowing, and speaking. In the last phase of an ALS patient's life it is necessary with respiratory therapy in order to breathe. In average an ALS patient lives 3 years from the time he or she gets the diagnose.
The cause of the disease is still unknown and there is currently no treatment which can stop the progression of the disease. Former clinical studies have indicated that the innate immune system and in particular the complement system plays a significant role in the progression of ALS. The complement system, which is activated in cascades, is part of the innate system but participates in the innate as well as the acquired immune system. Former clinical trials have been characterized by limited knowledge about both the complement system as well as to how it is measured.
Today it is possible to measure directly on the different components of the complement system and to understand its contribution to the overall immune response. It is also possible today to detect defects of the complement system. All these progressions are the foundation for this project which is carried out in close cooperation with one of the world's leading researchers in the complement system, professor Peter Garred from Rigshospitalet.
The aim is to make a national research project about ALS in order to investigate the role of the innate immune system, and especially the complement system, in patients with ALS.
In the long term the hope is, that this will lead the way to a targeted and effective medical treatment to the people affected by this grave disease.
|Condition or disease|
|Amyotrophic Lateral Sclerosis Neurodegenerative Disease Motor Neuron Disease|
Show Detailed Description
|Study Type :||Observational|
|Estimated Enrollment :||375 participants|
|Official Title:||Amyotrophic Lateral Sclerosis and the Innate Immune System|
|Study Start Date :||June 2016|
|Estimated Primary Completion Date :||June 2026|
|Estimated Study Completion Date :||June 2026|
Patients diagnosed with ALS will be included in this group. Blood and spinal fluid samples will be stored in biobank and later analyzed. A subset of this group (20 ALS patients) will give blood and spinal fluid every 6 months during progression of the disease. A subset of 10 will donate a muscle biopsy.
Control group with patients with other neurological disease
Patients referred to hospital with symptoms of acute or chronic headache.
Neurologically healthy control group
Patients having orthopaedic surgery performed in spinal anaesthesia.
- Complement activity [ Time Frame: 0-10 year ]The complement activity (measured by haemolytic capacity, complement-activation potential and specific mediators) in ALS patients and compared with 2 control groups.
- Subcomponents of the complement cascade [ Time Frame: 0-10 years ]If increased complement activity is found, the amount of the different subcomponents of the complement cascade are measured and compared with the 2 control groups.
- Inactivation of the complement system [ Time Frame: 0-2 years ]The effect of inactivation by heat or inhibition of the complement system with anti-complement in the plasma is analyzed by comparing the degree of haemolysis after incubation compared with the test results of the plasma which is not inactivated by heat nor with added anti-complement.
- Indirect profiling of inflammatory proteins present in the blood [ Time Frame: 0-10 years ]RNA expression profile of the ALS patients compared with the 2 control groups
- Cytokines present in the blood [ Time Frame: 0-10 years ]The cytokines are measured in ALS patients and compared with the 2 control groups.
- Acut phase reactants [ Time Frame: 0-10 years ]The acute phase reactants are measured in ALS patients and compared with the 2 control groups.
- Complement activity in the neuromuscular junctions of ALS patients. (Clinical trial 4) [ Time Frame: 0-3 years ]The amount of complement deposition as well as complement activity in the neuromuscular junctions are described quantitatively as well as qualitatively
- Quantitatively and qualitatively description of ALS muscle fibers. [ Time Frame: 0-3 years ]The muscle fibres are described quantitatively as well as qualitatively and compared historically collected material of healthy muscle fibers.
- Regression analysis [ Time Frame: 0-10 years ]The immune response of the ALS patients is analyzed as a function of sex, age, subtype of disease, stage of disease, severity of disease, duration of disease, present smoking, alcohol consumption, present use of medicine (including riluzole). The regression analysis will be compared when possible with the 2 control groups (sex, age, smoking, alcohol consumption, use of medicine).
Biospecimen Retention: Samples With DNA
Serum, EDTA-plasma, Hirudin-plasma, Heparin-plasma and RNAlater samples (with fullblood) will be kept in biobank as well as analyzed according design and methods of Clinical study 1+2+3.
Spinal liquid sample will also be kept in biobank (Clinical Study 2+3).
10 muscle biopsies from ALS patients will be analyzed (Clinical study 4)
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02869048
|Contact: Anne-Lene Kjældgaard, MDemail@example.com|
|Dept. of Neurology Aarhus Hospital, Nørrebrogade||Recruiting|
|Aarhus, Denmark, 8000|
|Contact: Anette Torvin Møller, MD, PhD|
|Gildhøj Private Hospital||Completed|
|Brøndby, Denmark, 2605|
|Dept. of Neurology, Bisbebjerg Hospital||Recruiting|
|Copenhagen NV, Denmark, 2400|
|Contact: Merete Karlsborg, MD|
|Clinic of Neurosurgery, Rigshospitalet||Not yet recruiting|
|Copenhagen Ø, Denmark, 2100|
|Contact: Marianne Juhler, dr.med, prof|
|Clinic of neuroanestesiology, Rigshospitalet Glostrup||Recruiting|
|Copenhagen, Denmark, 2600|
|Contact: Anne-Lene Kjældgaard, MD|
|The Dept. og Neurology, Rigshospitalet Glostrup||Recruiting|
|Glostrup, Denmark, 2600|
|Contact: Elisabeth Elmo, MD|
|Dept. of Neurology, Odense Hospital||Recruiting|
|Odense C, Denmark, 5000|
|Contact: Matthias Bode, MD|
|The dept. of Neurology, Roskilde Hospital||Recruiting|
|Roskilde, Denmark, 4000|
|Contact: Helle Thagesen, MD|
|Study Chair:||Kirsten Møller, Prof., MD||Clinic of Neuroanestesiology, Rigshospitalet, Denmark|
|Study Chair:||Peter Garred, Prof., MD||Department of Clinical Immunology|
|Study Chair:||Stephen Wørlich Pedersen, dr.med||Dept. of Neurology, Rigshospitalet Glostrup|
|Study Chair:||Karsten Skovgaard Olsen, Dr.med.||Clinic of Neuroanaestesiology, Rigshospitalet Glostrup|
|Study Chair:||Anne Øberg Lauritsen, MD||Clinic of Neuroanaestesiology, Rigshospitalet Glostrup|
|Study Chair:||Eva Løbner Lund, MD, PhD||Dept. of Pathology, Rigshospitalet|
|Principal Investigator:||Anne-Lene Kjældgaard, MD||Clinic of Neuroanaestesiology, Rigshospitalet Glostrup|